Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21051376 | 1.00 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL21051363 | 1.00 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL2449880 | 0.95 | PRKAB2 (0.46) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL21051390 | 0.91 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL21051391 | 0.91 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL21051399 | 0.91 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL2450470 | 0.91 | HPGD (0.46) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL2450469 | 0.91 | HPGD (0.46) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL2449399 | 0.85 | MIF (0.49) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2446420 | 0.85 | TDP1 (0.66) | RAB9ANPC1SMN1; SMN2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2019-06-13 | — | — | US | disclosed |
| EP-2006351-B1 | LIQUID-CRYSTALLINE COMPOSITION WITH IMPROVED ADHESION, LIQUID-CRYSTAL FILM COMPRISING THE COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT EMPLOYING THE FILM | NIPPON OIL CORP (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-1422255-B1 | MAIN CHAIN TYPE LIQUID CRYSTAL POLYESTER LIQUID CRYSTALLINE COMPOSITION METHOD FOR PRODUCING LIQUID CRYSTAL FILM OPTICAL FILM AND DISPLAY | NIPPON OIL CORP (JP) | 2011-09-28 | — | — | EP | disclosed |
| CN-101874215-A | Method for producing optical film | NIPPON OIL CORP | 2010-10-27 | — | — | CN | disclosed |
| US-20100208182-A1 | METHOD FOR MANUFACTURING OPTICAL FILM | NIPPON OIL CORPORATION (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7763182-B2 | Liquid crystalline composition with improved adhesivity, liquid crystal film comprising the composition, and liquid crystal display device equipped with the film | NIPPON OIL CORPORATION (JP) | 2010-07-27 | — | — | US | disclosed |
| EP-2202546-A1 | METHOD FOR PRODUCING OPTICAL FILM | Nippon Oil Corporation (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20090208673-A1 | Liquid Crystalline Composition with Improved Adhesivity, Liquid Crystal Film Comprising the Composition, and Liquid Crystal Display Device Equipped with the Film | NIPPON OIL CORPORATION (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2006351-A9 | LIQUID-CRYSTALLINE COMPOSITION WITH IMPROVED ADHESION, LIQUID-CRYSTAL FILM COMPRISING THE COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT EMPLOYING THE FILM | Nippon Oil Corporation (JP) | 2009-07-01 | — | — | EP | disclosed |
| EP-2006351-A2 | LIQUID-CRYSTALLINE COMPOSITION WITH IMPROVED ADHESION, LIQUID-CRYSTAL FILM COMPRISING THE COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT EMPLOYING THE FILM | Nippon Oil Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| CN-101246284-A | Method for manufacturing optical film | NIPPON OIL CORP (JP) | 2008-08-20 | — | — | CN | disclosed |
| US-6894141-B2 | Main chain type liquid crystalline polyester, liquid crystalline composition, method for producing liquid crystal film and optical film, and display having optical film | NIPPON OIL CORPORATION (JP) | 2005-05-17 | — | — | US | disclosed |
| US-20040171788-A1 | Main chain type liquid crystal polyester, liquid crystalline composition, method for producing liquid crystal film, optical film and display | NOBLE VENTURE FINANCE I LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1422255-A1 | MAIN CHAIN TYPE LIQUID CRYSTAL POLYESTER LIQUID CRYSTALLINE COMPOSITION METHOD FOR PRODUCING LIQUID CRYSTAL FILM OPTICAL FILM AND DISPLAY | Nippon Oil Corporation (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE4A | RAB9A 292/4885NPC1 3214/4885SMN1; SMN2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.